$14.6M NINDS Award Will Advance Gene Therapy From Ohio State Team

$14.6M NINDS Award Will Advance Gene Therapy From Ohio State Team

311620

$14.6M NINDS Award Will Advance Gene Therapy From Ohio State Team

The ongoing clinical evaluation of a new gene therapy to treat aromatic L-amino acid decarboxylase (AADC) deficiency has been boosted by a $14.6 million award from the National Institute of Neurological Disorders and Stroke (NINDS). Researchers at The Ohio State University Wexner Medical Center and College of Medicine have found that the investigational gene therapy dramatically improves motor function and quality of life in AADC children in a Phase 1 clinical trial (NCT02852213). The grant…

You must be logged in to read/download the full post.